Q1 2025 revenue fell 5.66% and net profit dropped 44.95% year-over-year, mainly due to higher sales and R&D expenses. Jinsai Pharma grew revenue but saw profit decline, while other segments posted significant drops.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.